title: [Effectiveness of thalidomide for erythema nodosum leprosum (ENL): retrospective study of 20 Japanese cases in National Sanatrium Oku-Komyoen].
abstract: Thalidomide is a TNF-alpha inhibitor and has been administrated for erythema nodosum leprosum (ENL, Type II leprosy reaction) which is one of leprosy reactions and can cause serious illness to patients oflepromatous pole among the immune spectrum. Twenty live cases (at May, 2011) were identified to whom thalidomide had been administrated since 1978 for their ENL reactions. Data were collected from their clinical records in order to evaluate the usage and effectiveness of thalidomide in National Sanatorium Oku-Komyoen, Okayama, Setouchi-city, Japan. Individual data includes bacillary index (BI), total dose, average daily dose, maximum daily dose, minimum daily dose, methods of thalidomide administration and change of symptoms of ENL. Results: No adverse effect was found among 20 cases. Average daily dose of 20 cases was 19 mg. Regarding to the maximum daily dose, in 3 cases (15%) more than 100 mg, in 3 cases (15%) 50 mg, and in 14 cases (70%) less than 40 mg was administrated. Dose was gradually tapered in most cases. From clinical records, thalidomide was found effective for ENL in 19 cases and clinicians concerned were trying to adjust the proper dose of the drug carefully depending on the current symptoms, because there was no guideline of thalidomide administration for ENL. This data suggests that even less than 50-100 mg as the initial daily dose was still effective, though 50-100 mg daily dose is recommended in the current guideline of Japan (2011) and more dose had been administrated in USA and India.
authors.forename: Takanobu
authors.initials: T
authors.lastname: Matsuki
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Okano
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Aoki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ishida
authors.forename: Kentaro
authors.initials: K
authors.lastname: Hatano
authors.forename: Kimiko
authors.initials: K
authors.lastname: Kumano
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People; D004334:Drug Administration Schedule; D004893:Erythema Nodosum / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007564:Japan; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007917:Leprostatic Agents; D013792:Thalidomide